Q1 Earnings Estimate for TSBX Issued By Leerink Partnrs

Turnstone Biologics Corp. (NASDAQ:TSBX) – Investment analysts at Leerink Partnrs issued their Q1 2026 earnings per share (EPS) estimates for shares of Turnstone Biologics in a report issued on Tuesday, April 1st. Leerink Partnrs analyst D. Graybosch expects that the company will earn ($0.13) per share for the quarter. The consensus estimate for Turnstone Biologics’ current full-year earnings is ($3.32) per share. Leerink Partnrs also issued estimates for Turnstone Biologics’ Q2 2026 earnings at ($0.13) EPS, Q3 2026 earnings at ($0.13) EPS and Q4 2026 earnings at ($0.13) EPS.

Turnstone Biologics (NASDAQ:TSBX) last released its quarterly earnings data on Friday, March 28th. The company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.69) by $0.13.

Separately, Piper Sandler cut Turnstone Biologics from an “overweight” rating to a “neutral” rating and reduced their price objective for the company from $3.75 to $0.40 in a research report on Wednesday, February 5th.

Turnstone Biologics Stock Up 1.0 %

Turnstone Biologics stock opened at $0.38 on Wednesday. Turnstone Biologics has a 12 month low of $0.34 and a 12 month high of $3.88. The stock has a market cap of $8.78 million, a P/E ratio of -0.12 and a beta of 2.04. The company’s fifty day simple moving average is $0.41 and its 200-day simple moving average is $0.47.

Institutional Trading of Turnstone Biologics

A hedge fund recently raised its stake in Turnstone Biologics stock. FMR LLC lifted its holdings in Turnstone Biologics Corp. (NASDAQ:TSBX) by 3.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,172,987 shares of the company’s stock after purchasing an additional 37,738 shares during the period. FMR LLC owned 5.07% of Turnstone Biologics worth $653,000 at the end of the most recent reporting period. 52.51% of the stock is owned by institutional investors.

Turnstone Biologics Company Profile

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas.